There are reports of TNF antagonists rarely promoting the development of demyelinating disease, and a potential underlying mechanism has been unravelled through the discovery of a multiple sclerosis-associated genetic variant that translates into the production of an endogenous TNF antagonist called Δ6-TNFR1 [143, 144]. The gene discussed is TNF; the disease is multiple sclerosis.